Skip to main content

Advertisement

Table 2 Predictive power of continuous and categorical CTC-counts for therapy response

From: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

  Radiographic evaluation Clinical criteria
CTC-assessment Interval Patients (n=) Odds Ratio 95 % CI p= Odds Ratio 95 % CI p=
Continuous CTC-values CTC q0 with OR at q4 33 1.0 0.99-1.02 0.53 1.0 0.99-1.04 0.17
CTC q1 with OR at q4 33 1.03 0.99-1.07 0.17 1.1 0.99-1.13 0.06
CTC q4 with OR at q4 33 1.04 1.0-1.09 0.048 1.1 1.03-1.26 0.009
CTC q10 with OR at q10 23 1.02 0.98-1.07 0.28 1.1 1.0-1.23 0.052
Categorical CTC-counts CTC q0 with OR at q4 33 6.5 0.7-60.5 0.1 8.0 0.86-74.2 0.07
CTC q1 with OR at q4 33 14.9 1.6-142.2 0.02 19.4 2.0-185.7 0.01
CTC q4 with OR at q4 33 18.0 1.9-174.2 0.01 24.0 2.5-233.5 0.006
CTC q10 with OR at q10 23 16.3 1.4-183.1 0.02 5.0 0.82-30.5 0.08
  1. q, cycle of docetaxel; OR, objective response
  2. p values indicate statistical significance